Labie D, Elion J
Institut Cochin de Génétique Moléculaire (ICGM), Faculté de Médecine Cochin-Port-Royal, Paris, France.
Pathol Biol (Paris). 1999 Jan;47(1):7-12.
The beta S mutation responsible for sickle cell disease (SCD) was identified in 1949. This mutation always consists in a T for A substitution at codon 6 of the beta-globin chain. Deoxygenated HbS becomes polymerized, producing erythrocyte shape changes and vasoocclusion. Still unexplained is the wide variability in clinical expression of SCD, whose spectrum ranges from severely incapacitating forms to virtually silent forms. Recent research has focused on genetic or environmental factors that may interfere with one or more steps of the basic pathophysiologic mechanisms. These factors can be roughly classified in three groups: i) factors that modify HbS levels within erythrocytes, thereby impacting the propensity of HbS for polymerization; ii) other normal or abnormal hemoglobins present in the erythrocyte that may modify side contacts of the hemoglobin molecule within the polymer, thus either stopping or enhancing polymerization; iii) molecules other than hemoglobin expressed at the surface of the SCD reticulocytes that may adhere to the vascular endothelium, thus slowing flow in the microcirculation and delaying HbS reoxygenation. Whatever the starting point, the same vicious circle is set in motion. These mechanisms have generally been studied separately, in vitro, under artificial conditions. An important goal is to understand how they interact in vivo in a given patient.
导致镰状细胞病(SCD)的βS突变于1949年被发现。该突变总是在于β珠蛋白链第6密码子处的A被T取代。脱氧的血红蛋白S(HbS)发生聚合,导致红细胞形状改变和血管阻塞。SCD临床表型的广泛变异性仍无法解释,其范围从严重致残形式到几乎无症状形式。最近的研究集中在可能干扰基本病理生理机制一个或多个步骤的遗传或环境因素上。这些因素大致可分为三类:i)改变红细胞内HbS水平的因素,从而影响HbS聚合的倾向;ii)红细胞中存在的其他正常或异常血红蛋白,它们可能改变聚合物内血红蛋白分子的侧链接触,从而阻止或增强聚合;iii)SCD网织红细胞表面表达的除血红蛋白以外的分子,它们可能粘附于血管内皮,从而减缓微循环中的血流并延迟HbS的再氧合。无论起点如何,都会启动相同的恶性循环。这些机制通常在体外人工条件下分别进行研究。一个重要目标是了解它们在特定患者体内如何相互作用。